Novo Nordisk has filed the final implementation of the reduction of the share capital with the Danish Commerce and Companies Agency, and as such the shares can be considered cancelled. After the reduction of the capital, the company's share capital is nominally DKK 709,388,320, which is divided into an A share capital of nominally DKK 107,487,200 and a B share capital of nominally DKK 601,901,120.
Holding of own shares
In the company's stock exchange announcement no 12 of 7 August 2001, it is stated that Novo Nordisk A/S and its wholly owned affiliates owned 31,516,705 of its own B shares corresponding to a total nominal value of DKK 63,033,410 or 8.36% of the total share capital.
Following the cancellation of nominally DKK 45 million of the company's own shares and with reference to Section 28 of the Danish Securities Trading Act, it is announced that Novo Nordisk A/S and its wholly owned affiliates as per 23 August 2001 own 9,011,205 of its own B shares. This corresponds to a total nominal value of DKK 18,022,410 B shares or 2.54% of the total share capital.
Novo Nordisk (NYSE:NVO) is a focused healthcare company and world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as coagulation disorders, growth disorders and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 15,000 people in 68 countries and markets its products in 179 countries. For further company information visit www.novonordisk.com.
For further information please contact:
Media:
Outside North America:
Karsten Madsen
Phone (direct): (+45) 4442 4137
Outside North America:
Karsten Madsen
Phone (direct): (+45) 4442 4137
In North America:
Susan Jackson
Phone (direct): (+1) 212 867 0123
Susan Jackson
Phone (direct): (+1) 212 867 0123
Investors:
Outside North America:
Peter Haahr
Phone (direct): (+45) 4442 1207
Outside North America:
Peter Haahr
Phone (direct): (+45) 4442 1207
Palle Holm Olesen
Phone (direct): (+45) 4442 6175
Phone (direct): (+45) 4442 6175
In North America
Rasmus Jorgensen
Phone (direct): (+1) 212 878 9607
Rasmus Jorgensen
Phone (direct): (+1) 212 878 9607
Stock Exchange Announcement No 13 / 2001